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(4) Medical Equipment Evaluation. This
programme's aims are to establish and
promote international protocols and
standards for Performance Testing,
Quality Assurance, Safety and
Environmental aspects.
22.
CURRENT STATUS OF SYSTEMATIC
RADIOPHARMACEUTICALS FOR
THE TREATMENT OF PAINFUL
METASTATIC BONR DISEASE
C. Pirich
Department of Nuclear Medicine, Vienna
University Hospital, Austria
Intractable bone pain secondary to bone
metastasis from prostate or breast cancer, or
other malignancies is a major problem in the
management of the oncological patient.
Treatment often includes the use of analgesic
drug therapy; however, radiation therapy,
hormonal therapy, chemotherapy, and surgery
mayaiso be needed. Advances in systemic
radionuciide therapy have increased the number
of treatment options available for patients with
painful osseous metastases. This treatment
modality offers three major advantages L) by
addressing all sites of involvement; and ii) by
limiting irradiation of normai tissues due to
selective absorption into bone which results in
an improved therapeutic ratio. Patients with a
positive bone scan are eligible for treatment,
and indications and contraindications for use are
well defined. Large, prospectively randomized
c1inical triais have established the efficacy of
samarium-153 EDTMP and strontium-89 CI as a
first-line therapy. When these agents are used,
pain relief often occurs rapidly and lasts several
weeks to months with responses seen in 60-
80% of patients, depending on the extent and
stage of the disease. With the introduction of
modern bone-seeking radiopharmaceuticals as
Sm-153 EDTMP toxicity is rare and restricted to
reversible myelosuppression. In summary,
evidenced based Iiterature suggests that these
radiopharmaceuticals can significantly reduce
pain and analgesic requirements, improve
quality of life, reduce lifetime radiotherapy
requirements and management costs, and may
even slow the progression of painful metastatic
lesions. Retreatment is safe and effective.
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PRINCIPLES OF RADIOIODINE
TREATMENT C31 I) FOR PATIENTS
WITH DIFFERENTIATED THYROID
CARCINOMAS
Jerzy Sowiński
Klinika Endokrynologii, Szpital kliniczny Nr 2,
Poznań
The aims of radioiodine C31 I) therapy for
patients with differentiated thyroid carcinomas:
D Destruction of thyroid tissue remaining after
thyroidectomy
D Destruction of microcarcinoma focus in site
of thyroid
D Destruction of metastases in Iymph nodes
D Destruction of distant metastases
Therapeutic indications for radioiodine
C31 I) treatment in differentiated thyroid
carcinomas
D Complementary treatment
This treatment is recommended in all patients
with follicular or papillary carcinomas in stage
pT1b-4 NO' 1 Mo after total thyroidectomy. In some
cases it could be as the complementary
treatment after incomplete thyroidectomy.
The recommended radioiodine activity for the
complementary therapy is from 1.75 to 3.5 GBq
(60 - 150 mCi)
D Radical treatment
This kind of treatment is recommended for
patients with differentiated thyroid carcinomas
and remote metastases. If the lesions
concentrate 131 I in quantities sufficient for
radical treatment - the patient can be treated
with the isotope.
D Palliative treatment
Palliative treatment is recommended for patients
with inoperable thyroid carcinoma or with local
recurrence, or with remote metastases
concentrating radioiodine in quantities non
sufficient for radical treatment.
Contraindications for radioiodine C31 I)
treatment
D Pregnancy
D Breast-feeding
The contraception for women is necessary
during 12 months after radioiodine treatment.
For men the 4 - 6 months contraception is
recommended.
Method of radioiodine C31 I) administration
D Patient serum TSH concentration should be
above 30 ulU/mi
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D Isotope administration is possible 4 - 6
weeks after total thyroidectomy or 4 -6
weeks after L-thyroxin treatment withdrawal
D radioiodine therapy should be tollowed by
body radioiodine scan pertormed at 72
hours after the therapeutic dose - to asses
foeuses eoncentrating radioiodine
D After administration of therapeutie
radioiodine dose the patient tor 14 days
should avoid to be in contact with other
persons, especially with children and
pregnant women
Complications after radioiodine C31 I)
treatment
The complications are very rare and usually
without clinical manitestations.
Follow-up after radioiodine C31 I) treatment
Follow-up at intervals 6 - 12 months after
radioiodine treatment should include careful
physical examination, neck ultrasonography,
needle biopsy examination is indicated it a lump
is noted. Serum thyroglobulin and TSH
concentration should be measured. Radioiodine
body sean should be pertormed 6 months after
treatment - after 4 - 6 weeks ot L-thyroxin
treatment withdrawal
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VALlDATION OF CONFORMAL
RADIOTHERAPY TREATMENT PLAN-
NING SYSTEMS USING AN ANTRO-
POMORPHIC PHANTOM AND THERMO-
LUMINESCENCE DOSIMETRY
M.P.R. Waligórski1,2, J. Lesiak\ E. Byrski\
B. Rozwadowska-Bogusz1, R. Barańczyk 1 ,
E. Góra\ P. Bilski2, P. Olko2
(1) Centre ot Oncology,
Garncarska 11, PL-30-115 Kraków, Poland
(2) Institute ot Nuelear Physics,
Radzikowskiego 152, PL-31-342 Kraków, Poland
Within the requirements ot a Quality
Assuranee programme in a radiotherapy
department, the ability ot a treatment planning
system (TPS) to accurately ealeulate dose
distributions under realistic conditions
encountered in radiotherapy (RT) should be
validated. This may be aceomplished by
thermoluminescence (TL) dosimetry in
simulated treatment ot antropomorphic
phantoms. In our radiotherapy department,
several planning systems are used concurrently
in 3D conformal treatment ot larger volumes
(with irregular fields obtained via individual
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shielding or multileat collimation) and ot very
smali volumes (stereotactie technique), by
external megavoltage photon beams. Realistic
3D treatment plans were prepared using
CadPlan, Theraplan and BrainLab TPS tor
treating volumes in an Alderson phantom, which
was prepared for topometry (CT-scanned) and
irradiated in tully simulated conditions of patient
RT. Suitably selected TL detectors (some
custom-produced tor these measurements),
were placed inside and around the treated
volumes in the phantom. For every photon
beam applied (Co-60, 6 MV or 9 MV) the TL
detectors, individually corrected, were calibrated
in a standard solid phantom against ionisation
chamber dosimetry. For irradiation ot larger
volumes, standard MTS-N (LiF:Mg,Ti) detectors
were used. For stereotactic irradiation ot smali
volumes in the head (6 MV) special miniature
thermoluminescent LiF:Mg,Ti and LiF:Mg,Cu,P
were developed. The teehnique ot detector
calibration, preparation ot Alderson phantom tor
simulated RT, detector readout and
interpretation ot the measured versus calculated
values ot dose at measurement points inside the
phantom, will be described.
25.
ASSESSMENT OF THE ACCURACY
OF RADlOTHERAPY BY DIGITAL
SUPERPOSITION OF PORTAL AND
RFERENCE IMAGES
P. Gut\ P. Kukołowicz 2, L. Chmielewski\
A. Dąbrowski 2
1 Institute ot Fundamental Technological Research,
PAS, Warsaw,
2 Holycross Cancer Centre, Kielce
Teleradiotherapy imposes the requirement ot
high accuracy in reterenee to its medical as
well as technical aspects. Close adherence to
the geometrical parameters set up in therapy
planning is vital. The current location ot the
irradiation tield and anatomical structures can be
recorded in the portal image acquired during the
therapy course. Assessment ot the treatment
accuracy consists in registration (overlaying) of
the reference and the portal image to compare
the layout ot anatomical structures and the
irradiation field. Edges of the compared features
are difficult to find in the portal image, which is
inherently of low contrasf. Hence, not all the
edges present in the reference image can be
found in the portal one, and the comparison ot
geometries in these images is difficult and time-
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